New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
09:12 EDTOWW, ORCL, KBH, PSUN, HZNP, EXAS, RENN, RBCNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: KB Home (KBH), up 7%...Pacific Sunwear (PSUN), up 7%. ALSO HIGHER: Horizon Pharma (HZNP), up 23% after deal to acquire Ireland's Vidara Therapeutics through reverse merger... Exact Sciences (EXAS), up 6.5% after a clinical trial of its Cologuard test, which it co-developed with the Mayo Clinic, showed "unprecedented" rates of precancer and cancer detection by a noninvasive test... DOWN AFTER EARNINGS: Oracle (ORCL), down 3.3%... Renren (RENN), down 7%. ALSO LOWER: Orbitz (OWW), down 5.4% after Goldman downgraded shares to Sell from Neutral... Rubicon (RBCN), down 6% after 2.5M share spot secondary offering priced at $13.00.
News For OWW;ORCL;KBH;PSUN;HZNP;EXAS;RENN;RBCN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 10, 2014
13:23 EDTRBCNRubicon halted for volatility after jumping 34% to $5.39
Subscribe for More Information
13:08 EDTEXASOn The Fly: Midday Wrap
Stocks on Wall Street opened in negative territory and saw several swings throughout the morning. Near midday the averages were mixed, with the Dow a bit higher and the Nasdaq weighed down by weakness across the semiconductor sector. ECONOMIC EVENTS: In the U.S., the import price index fell 0.5% in September, versus expectations for a 0.7% decline. COMPANY NEWS: Shares of a number of semiconductor makers, including industry giant Intel (INTC), were sharply lower after one of the companies in the space, Microchip Technology (MCHP), warned that it believes the sector has entered a correction. Microchip President and CEO Steve Sanghi claimed his company often sees the turn of the semiconductor industry ahead of others, noting that it does business with over 80,000 customers and that it built a significant amount of inventory in the distribution channel in the September quarter. Sanghi stated, "We believe that another industry correction has begun and that this correction will be seen more broadly across the industry in the near future. Near noon, Microchip dropped 11%, Intel fell almost 4%, Texas Instruments (TXN) slipped over 6%, Micron (MU) dropped 6% and Fairchild (FCS) declined 12%. MAJOR MOVERS: Among the notable gainers was Exact Sciences (EXAS), which rallied 35% after the company announced last night that the Centers for Medicare & Medicaid Services, or CMS, had agreed to cover the company's colorectal cancer and pre-cancer test through Medicare. Among the noteworthy losers were a number of companies that, similarly to Microchip, warned that their quarterly results will likely miss expectations, including Procera Networks (PKT), which plunged 34%, Manitowoc (MTW), which fell 9%, and Sizmek (SZMK), which dropped 21%. INDEXES: Near midday, the Dow was up 38.02, or 0.23%, to 16,697.27, the Nasdaq was down 35.89, or 0.82%, to 4,342.45, and the S&P 500 was up 0.42, or 0.02%, to 1,928.63.
11:18 EDTEXASOptions with decreasing implied volatility
Subscribe for More Information
11:05 EDTEXASExact Sciences jumps after CMS agrees to cover cancer test
Subscribe for More Information
09:30 EDTKBHKB Home upgraded to Outperform from Sector Perform at FBN Securities
FBN Securities upgraded KB Home to Outperform based on relative valuation and increased balance sheet leverage.
09:00 EDTEXASOn The Fly: Pre-market Movers
Subscribe for More Information
07:50 EDTEXASExact Sciences to see significant short squeeze on CMS decision, says Canaccord
Subscribe for More Information
07:32 EDTEXASExact Sciences price target raised to $27 from $20 at Jefferies
Subscribe for More Information
07:16 EDTEXASExact Sciences CMS decision a 'major positive' for shares, says Mizuho
Subscribe for More Information
07:12 EDTEXASExact Sciences price target raised to $34 from $28 at JMP Securities
JMP Securities increased its price target on Exact Sciences after CMS stated that the company's colorectal screening tool would be covered by Medicare and granted the company's request to price the test at $502. The firm thinks Cologuard will become the standard of care for the detection of colorectal cancer. It reiterates an Outperform rating on the stock. .
October 9, 2014
18:47 EDTEXASOn The Fly: After Hours Movers
UP AFTER EARNINGS: Helen of Troy (HELE), up 3%... Barracuda Networks (CUDA), up marginally after reporting second quarter results. ALSO HIGHER: Sucampo Pharmaceuticals (SCMP), up 19.2% after announcing settlement agreement resolving patent litigation on AMITIZA... Civeo (CVEO), up 15% after Greenlight Capital reported a 9.99% stake in the company... EXCO Resources (XCO), up 10.6% after T. Boone Pickens says that company approached by buyers, reported by Bloomberg... EXACT Sciences (EXAS), up 3.7% after announcing final national coverage determination for Cologuard... US Ecology (ECOL), up 2.5% following announcement that it will replace Measurement Specialties (MEAS) in S&P 600. DOWN AFTER EARNINGS: Procera Networks (PKT), down 19.3%... Sizmek (SZMK), down 13.9% following third quarter revenue guidance... VOXX International (VOXX), down 12.5%... Knowles (KN), down 8.1% after lowering third quarter guidance... Microchip (MCHP), down 8.2% after lowering second quarter guidance... Juniper Networks (JNPR), down 3.6% after lowering third quarter outlook. ALSO LOWER: GT Advanced Technologies (GTAT), down 23.3% following a Bloomberg report that it will as to wind down sapphire operations.
18:20 EDTEXASExact Sciences announces final national coverage determination for Cologuard
Subscribe for More Information
16:49 EDTORCLOracle hires former director of engineering from Google, Re/code reports
Oracle (ORCL) hired Peter Magnusson, former director of engineering at Google (GOOG) and VP of engineering at Snapchat, two weeks ago in a move to improve its cloud computing business, Re/code reports, citing sources familiar with the move. Reference Link
15:31 EDTHZNPHorizon Pharma's Actimmune Phase 2 results provide more growth, says Avondale
Avondale said Horizon Pharma's Actimmune Phase 2 results were strong and support incremental annual market opportunity of approximately $300K per year. The firm views the results as another potential growth driver and its Outperform rating and $22 price target.
13:40 EDTHZNPHorizon Pharma presents ACTIMMUNE Phase 2 data
Subscribe for More Information
October 7, 2014
14:58 EDTRBCNRubicon Technology volatility increases on wide price movement
Subscribe for More Information
10:14 EDTRBCNRubicon strength attributed to smartwatch speculation
Subscribe for More Information
09:02 EDTKBHKB Home acquires Houston property for Hollister Commons community
KB Home announced it has acquired land for a new community called Hollister Commons in Houstons sought-after Spring Branch submarket. The community is anticipated to open in the summer of 2015.
October 6, 2014
10:04 EDTORCLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:53 EDTORCLOracle upgraded to Buy from Neutral at DA Davidson
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use